Premium
Intrathecal application of autologous bone marrow cell preparations in parkinsonian syndromes
Author(s) -
Storch Alexander,
Csoti Ilona,
Eggert Karla,
Henriksen Tove,
Plate Annika,
Lorrain Michael,
Oertel Wolfgang H.,
Antonini Angelo
Publication year - 2012
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.24920
Subject(s) - medicine , parkinsonism , atrophy , parkinson's disease , disease , movement disorders , surgery , degenerative disease , retrospective cohort study , central nervous system disease
Background: A growing number of patients is treated with intrathecal application of autologous bone marrow cells (aBMCs), but clinical data are completely lacking in movement disorders. We provide first clinical data on efficacy and safety of this highly experimental treatment approach in parkinsonian syndromes. Methods: Retrospective data collection from patients with parkinsonism who spontaneously sought cell treatment. The application procedure was neither recommended nor performed by the authors. Results: We report 17 patients with parkinsonian syndromes (Parkinson's disease [PD], n = 7; multiple system atrophy [MSA], n = 7; various, n = 3) who received intrathecal application of aBMCs. We did not observe any changes in motor function, activities of daily living, global clinical impression, or antiparkinsonian medication after a median observation period of 10 months. Two patients reported a worsening of parkinsonian symptoms, but the intervention was otherwise safe and well‐tolerated. Conclusions: Intrathecal application of aBMCs in uncontrolled conditions produces no clinical benefit in parkinsonian syndromes. © 2012 Movement Disorder Society